Paul Dent

29.1k citations

388 papers · 23.1k indexed · 4 hit papers · h-index 81

Oncology top 0.2%
- Cancer-related Molecular Pathways 52
Molecular Biology top 0.1%
- Cell death mechanisms and regulation 75
- Histone Deacetylase Inhibitors Research 62
- Melanoma and MAPK Pathways 49
- Protein Kinase Regulation and GTPase Signaling 45
- PI3K/AKT/mTOR signaling in cancer 34
Cell Biology top 0.2%
- Endoplasmic Reticulum Stress and Disease 37
Cancer Research top 0.5%
Hematology top 0.5%
Epidemiology
- Autophagy in Disease and Therapy 55

Co-authors: Steven Grant Mohamed Rahmani Paul B. Fisher Thomas W. Sturgill Adly Yacoub Yun Dai Kristoffer Valerie Laurence Booth
Cited by: Oncology Molecular Biology Cell Biology
Journals: Cancer Biology & Therapy (41 papers)Molecular Pharmacology (33 papers)Blood (23 papers)
Partner nations: United States Russia Canada

In The Last Decade

Paul Dent

387 papers receiving 22.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Paul Dent

Since Specialization

Citations

This map shows the geographic impact of Paul Dent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Dent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Dent more than expected).

Fields of papers citing papers by Paul Dent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Dent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Dent. The network helps show where Paul Dent may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paul Dent, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Dent Line = papers co-authored together Paul Dent links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells Oncotarget ·Laurence Booth,Jane L. Roberts,Cameron West,Paul Dent	2024	2
2	AR‐12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication Journal of Cellular Physiology ·Laurence Booth,Jane L. Roberts,Heath Ecroyd,Sarah R. Tritsch,Sina Bavari,St. Patrick Reid,Stefan Proniuk,Alexander Zukiwski,Abraham Jacob,Claudia S. Sepúlveda,Federico Giovannoni,Cybele C. Garcı́a,Elsa B. Damonte,Javier González‐Gallego,María J. Tuñón,Paul Dent	2016	33
3	CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies Cancer Research ·Shuang Chen,Yun Dai,Adi Domenico,A.S Fulginiti,Li Wang,Lora B. Kramer,P.J. Broadway,Daniella M. Schwartz,Yinchuan Guo,Gary Simmons,김명연,bulletproof,Paul Dent,Robert Z. Orlowski,Steven Grant	2012	46
4	MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma Cancer Research ·Swadesh K. Das,Sujit K. Bhutia,Belal Azab,Timothy P. Kegelman,Alejandro Olguín-Lamas,Prasanna K. Santhekadur,Santanu Dasgupta,Rupesh Dash,Paul Dent,Steven Grant,Luni Emdad,Maurizio Pellecchia,Devanand Sarkar,Paul B. Fisher	2012	79
5	Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells Cancer Research ·Jose G. Machain Palacio,Margaret A. Park,Adly Yacoub,Hossein A. Hamed,Yong Tang,Nichola Cruickshanks,Patrick Eulitt,Stanko Vrabec,Gary Tye,Matthew E. Burow,Paul B. Fisher,Richard G. Moran,Kenneth P. Nephew,Steven Grant,Paul Dent	2011	97
6	Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda -7/IL-24–mediated toxicity Proceedings of the National Academy of Sciences ·Rupesh Dash,Belal Azab,Bridget A. Quinn,Xue‐Ning Shen,Xiangyang Wang,Swadesh K. Das,Mohamed Rahmani,Jun Wei,Michael Hedvat,Paul Dent,Igor P. Dmitriev,David T. Curiel,Steven Grant,Bainan Wu,John L. Stebbins,Maurizio Pellecchia,John C. Reed,Devanand Sarkar,Paul B. Fisher	2011	101
7	Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+- De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling Pathway Cancer Research ·Margaret A. Park,Clint Mitchell,Guo Zhang,Adly Yacoub,Jeremy C. Allegood,Dieter Häussinger,Roland Reinehr,Andrew C. Larner,Sarah Spiegel,Paul B. Fisher,Christina Voelkel‐Johnson,Besim Öğretmen,Steven Grant,Paul Dent	2010	86
8	Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells Molecular Cancer Therapeutics ·Margaret A. Park,Roland Reinehr,Dieter Häussinger,Christina Voelkel‐Johnson,Besim Öğretmen,Adly Yacoub,Steven Grant,Paul Dent	2010	74
9	Mechanism of Autophagy to Apoptosis Switch Triggered in Prostate Cancer Cells by Antitumor Cytokine Melanoma Differentiation-Associated Gene 7/Interleukin-24 Cancer Research ·Sujit K. Bhutia,Rupesh Dash,Swadesh K. Das,Belal Azab,Zhao-zhong Su,Seok‐Geun Lee,Steven Grant,Adly Yacoub,Paul Dent,David T. Curiel,Devanand Sarkar,Paul B. Fisher	2010	102
10	PERK–Dependent Regulation of Ceramide Synthase 6 and Thioredoxin Play a Key Role in mda -7/IL-24–Induced Killing of Primary Human Glioblastoma Multiforme Cells Cancer Research ·Adly Yacoub,Hossein A. Hamed,Jeremy C. Allegood,Clint Mitchell,Sarah Spiegel,Maciej S. Lesniak,Besim Öğretmen,Rupesh Dash,Devanand Sarkar,William C. Broaddus,Steven Grant,David T. Curiel,Paul B. Fisher,Paul Dent	2010	89
11	17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca2+-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species Molecular Cancer Therapeutics ·Teneille Walker,Clint Mitchell,Margaret A. Park,Adly Yacoub,Mohamed Rahmani,Dieter Häussinger,Roland Reinehr,Christina Voelkel‐Johnson,Paul B. Fisher,Steven Grant,Paul Dent	2010	16
12	Targeting Sphingosine Kinase 1 Inhibits Akt Signaling, Induces Apoptosis, and Suppresses Growth of Human Glioblastoma Cells and Xenografts Cancer Research ·Dmitri Kapitonov,Jeremy C. Allegood,Clint Mitchell,Nitai C. Hait,Jorge A. Almenara,Jeffrey K. Adams,Robert E. Zipkin,Paul Dent,Tomasz Kordula,Sheldon Milstien,Sarah Spiegel	2009	154
13	MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism Molecular Cancer Therapeutics ·Margaret A. Park,Teneille Walker,Aditi Pandya Martin,Jeremy C. Allegood,Nicollaq Vozhilla,Luni Emdad,Devanand Sarkar,Mohamed Rahmani,Martin Graf,Adly Yacoub,Constantinos Koumenis,Sarah Spiegel,David T. Curiel,Christina Voelkel‐Johnson,Steven Grant,Paul B. Fisher,Paul Dent	2009	40
14	Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation Clinical Cancer Research ·Guo Zhang,Margaret A. Park,Clint Mitchell,Hossein A. Hamed,Mohamed Rahmani,Aditi Pandya Martin,David T. Curiel,Adly Yacoub,Martin R. Graf,Ray Lee,John D. Roberts,Paul B. Fisher,Steven Grant,Paul Dent	2008	101
15	Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95 Molecular Cancer Therapeutics ·Margaret A. Park,Guo Zhang,Clint Mitchell,Mohamed Rahmani,Hossein A. Hamed,Michael P. Hagan,Adly Yacoub,David T. Curiel,Paul B. Fisher,Steven Grant,Paul Dent	2008	41
16	Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells Clinical Cancer Research ·Yun Dai,Shuang Chen,Lora B. Kramer,Luis Eduardo Pariente Zorrilla,Paul Dent,Steven Grant	2008	68
17	Extracellular Signal-Related Kinase Positively Regulates Ataxia Telangiectasia Mutated, Homologous Recombination Repair, and the DNA Damage Response Cancer Research ·Sarah E. Golding,Elizabeth Rosenberg,Steven J. Neill,Paul Dent,Lawrence F. Povirk,Kristoffer Valerie	2007	145
18	Involvement of Sphingosine Kinase 2 in p53-Independent Induction of p21 by the Chemotherapeutic Drug Doxorubicin Cancer Research ·Heidi Sankala,Nitai C. Hait,Steven W. Paugh,Dai Shida,Sandrine Lépine,Lynne W. Elmore,Paul Dent,Sheldon Milstien,Sarah Spiegel	2007	132
19	RLIP76 Is a Major Determinant of Radiation Sensitivity Cancer Research ·Sanjay Awasthi,Sharad S. Singhal,Sushma Yadav,Jyotsana Singhal,Kenneth Drake,Esther Decimavilla Herrero,Ewa Zając,Dilki Wickramarachchi,Saeed El-Ashker,Adly Yacoub,Peter Boor,Seema Dwivedi,Paul Dent,HlDEAKI ISHIKURA,Vasko Bogdanovski	2005	79
20	Raf-1 Kinase Activation by Angiotensin II in Adrenal Glomerulosa Cells: Roles of Gi, Phosphatidylinositol 3-Kinase, and Ca2+ Influx Endocrinology ·Roger Smith,Albert J. Baukal,Paul Dent,Kevin Catt	1999	44

About Paul Dent

Paul Dent is a scholar working on Oncology, Molecular Biology, Cell Biology, Physiology and Hematology, having authored 388 papers that have together received 23.1k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (75 papers), Histone Deacetylase Inhibitors Research (62 papers), Autophagy in Disease and Therapy (55 papers), Cancer-related Molecular Pathways (52 papers), Melanoma and MAPK Pathways (49 papers), Protein Kinase Regulation and GTPase Signaling (45 papers), Endoplasmic Reticulum Stress and Disease (37 papers) and PI3K/AKT/mTOR signaling in cancer (34 papers). The work is most often cited by research in Oncology (7.0k citations), Molecular Biology (15.6k citations), Cell Biology (2.8k citations), Cancer Research (2.4k citations) and Hematology (1.6k citations). Paul Dent has collaborated with scholars based in United States, Russia and Canada. Frequent co-authors include Steven Grant, Mohamed Rahmani, Paul B. Fisher, Thomas W. Sturgill, Adly Yacoub, Yun Dai, Kristoffer Valerie, Laurence Booth, Rupert Schmidt‐Ullrich and Michael P. Hagan. Their work appears in journals such as Cancer Biology & Therapy, Molecular Pharmacology, Blood, Molecular Cancer Therapeutics and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact